Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist illustration of a nano-rocket and a drug capsule on a solid background.

May 13, 2026

Hong Kong-listed firm uses AI to make nano-rockets to deliver life-saving drugs

METiS TechBio, a Hong Kong-based startup, is revolutionizing drug delivery using AI technology, evidenced by a remarkable 173% surge in its stock price during its debut. This strong market response highlights the growing investor interest in AI-driven healthcare innovations.The company, which focuses on AI-enhanced drug design, priced its initial public offering at HK$10.50 per share, but it opened at HK$28.68, reflecting high demand. Co-founder and CEO Lai Tsai-Ta emphasized that their AI algor
Flat illustration of siRNA molecule and AI brain icon

May 12, 2026

Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI

Suzhou Ribo Life Science Co., Ltd. has forged a strategic partnership with Insilico Medicine to enhance the development of siRNA therapeutics using AI technologies.The collaboration focuses on integrating artificial intelligence into various stages of siRNA drug development, including target discovery and drug optimization. By combining Ribo's expertise in siRNA technology with Insilico's AI-driven drug discovery platform, the partnership aims to accelerate the creation of innovative therapies t
Minimalist illustration of a pluripotent stem cell and dopaminergic progenitor

May 12, 2026

AI to accelerate Novo Nordisk's Parkinson’s cell therapy

Novo Nordisk is partnering with Cellular Intelligence to enhance its Parkinson's cell therapy through AI technology, aiming to streamline development and commercialization processes.The collaboration allows Cellular Intelligence to leverage its AI foundation model to optimize Novo Nordisk's allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, which is currently undergoing a Phase I/II clinical trial. This innovative approach is designed to significantly reduce the time requi
A small molecule drug compound on a lab bench with chemical reagents in the background.

May 11, 2026

AI cancer-therapy firm Lantern Pharma plans May 15 Q1 results

Lantern Pharma, a clinical-stage company specializing in AI-driven precision oncology, is set to release its Q1 2026 financial results on May 15, 2026. The upcoming report will cover the company's financial performance for the first quarter ending March 31, 2026, along with updates on its clinical trials and advancements in its AI technology. Lantern Pharma utilizes its proprietary AI and machine learning platform, RADR®, to enhance the drug discovery process for challenging cancers, including c
A petri dish with cell culture in a laboratory setting

May 11, 2026

Novo turns a Parkinson’s bet into a startup test

Novo Nordisk has transitioned its clinical-stage Parkinson's cell therapy, STEM-PD, to Cellular Intelligence, an AI-focused biotech supported by the Chan Zuckerberg Initiative. This strategic licensing deal illustrates a growing trend among pharmaceutical companies to offload non-core assets into specialized startups while maintaining a stake in their success through equity and potential royalties.By transferring STEM-PD, Novo Nordisk is not merely divesting a project but strategically managing
A glass flask with a colorful chemical compound in a dimly lit lab setting.

May 11, 2026

A year of advancing the Lilly-Purdue $250M research partnership to accelerate medicine discovery and manufacturing

The Lilly-Purdue partnership is making significant strides in pharmaceutical innovation and research, following its launch in May 2025.Since the announcement of a $250 million collaboration, Purdue University and Eli Lilly and Company have actively engaged in developing a shared research agenda aimed at enhancing drug discovery and manufacturing processes. This partnership, known as the Lilly-Purdue 360 Initiative, is notable for being the largest industry-academic agreement of its kind in the U
A stock certificate and financial report on a desk

May 8, 2026

Schrodinger Inc stock (US80655G1067): Q1 loss and revenue miss weigh on shares

Schrodinger Inc's recent financial performance has raised concerns among investors, as the company reported a larger-than-expected loss and fell short of revenue forecasts for Q1 2026, leading to a decline in its stock price.On May 7, 2026, Schrodinger's shares were trading at approximately $13.28 on Nasdaq. The company disclosed a net loss of around $60 million, or $0.81 per share, which is slightly worse than the previous year's loss of $59.8 million. This financial outcome has intensified scr
Minimalist illustration of an antibody and target

May 8, 2026

Europe's $154+ Million AI in Antibody Discovery Market,

The European market for AI in antibody discovery is poised for significant growth, projected to expand from approximately $153.8 million in 2025 to $1.43 billion by 2035, reflecting a compound annual growth rate (CAGR) of 25.05%.This growth is largely driven by the limitations of traditional antibody discovery methods, which are often costly and time-consuming. The integration of advanced technologies such as deep learning and generative AI is transforming the landscape, enabling more efficient
Close-up of human immune cells on a glass slide in a laboratory setting.

May 8, 2026

AstraZeneca Expands AI Biotech Partnership With Immunai Through 2027

AstraZeneca has strengthened its partnership with Immunai, focusing on AI-driven advancements in oncology and beyond. This collaboration, now extended through 2027, underscores the pharmaceutical giant's commitment to integrating cutting-edge technology into its drug development processes.The latest agreement allows Immunai to potentially earn up to $37.5 million as AstraZeneca leverages Immunai’s AMICA-OS platform, which utilizes AI to model the human immune system through extensive clinical da
Model of the human immune system in a research lab

May 7, 2026

AstraZeneca expands AI partnership with Immunai in deal worth up to $37.5 million

AstraZeneca is enhancing its collaboration with Immunai, focusing on artificial intelligence for oncology drug development. The expanded partnership could yield up to $37.5 million for Immunai through 2027, underscoring the increasing significance of AI technologies in pharmaceutical research.This collaboration builds on an existing relationship that began in 2024, with AstraZeneca utilizing Immunai's AMICA-OS platform. This AI-driven system models the human immune system, leveraging one of the
A minimalist illustration of a financial report with a rising chart

May 6, 2026

RVTY Q1 2026 Deep Dive: Portfolio Pruning and AI Investments Shape Outlook

Revvity's Q1 2026 results reveal a mixed performance with a focus on strategic adjustments and AI investments.Revvity (NYSE:RVTY) reported a 9.3% year-on-year revenue increase, totaling $686.9 million for Q1 CY2026, but fell short of market expectations, which were set at $705.1 million. Despite this, the company exceeded adjusted earnings per share (EPS) estimates, delivering $1.06 compared to the expected $1.01. The firm also adjusted its full-year revenue guidance downward to $2.83 billion fr
A minimalist illustration of a pill and a molecule in a dark palette.

May 6, 2026

AI in Drug Development: Where Value is Emerging

The integration of AI into drug development is reshaping the pharmaceutical landscape, promising faster and more cost-effective processes.The pharmaceutical sector is characterized by lengthy development timelines, substantial financial commitments, and high failure rates. AI emerges as a potential game-changer, aiming to streamline drug discovery and enhance success rates. However, the diverse nature of AI technologies and the extended timelines required for drug development make it challenging